• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Trials of primary prevention by diet or hypolipidemic treatment].

作者信息

Richard J L

机构信息

INSERM, Unité de recherche d'épidémiologie cardiovasculaire (Unité 258), hôpital Broussais, Paris.

出版信息

Arch Mal Coeur Vaiss. 1992 Sep;85 Spec No 2:97-103.

PMID:1285703
Abstract

The experimental demonstration of a causal relationship between serum cholesterol and coronary artery disease has been confirmed by primary prevention trials. Four trials have fulfilled the methodological criteria of this type of research. Three of them have involved lipid lowering drugs (clofibrate, cholestyramine and gemfibrozil) and the fourth a diet low in saturated fats. They were undertaken in middle aged hypercholesterolemic men and offered 9 out of 10 chances of demonstrating a significant reduction in the prevalence in ischaemic heart disease if it existed. The serum cholesterol of the treatment groups was on average 8 to 13% lower to that of the control groups. In the 4 trials, the prevalence of severe coronary events, infarction and sudden death, was significantly reduced (relative reduction of 19 to 47%). The reduction in individual risk was proportional to the reduction in serum cholesterol. In 2 trials, this reduction was related to variations in the opposite directions of the LDL and HDL cholesterol: a reduction of 1% in LDL-cholesterol reduced the risk by 2% and an increase of 1% of HDL-cholesterol reduced it by 2 to 4%. None of the trials were designed to evaluate the effect of intervention on mortality. In one of them (clofibrate), all cases of mortality were temporarily increased during the trial.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
[Trials of primary prevention by diet or hypolipidemic treatment].
Arch Mal Coeur Vaiss. 1992 Sep;85 Spec No 2:97-103.
2
[Statins in primary prevention of coronary heart disease].[他汀类药物在冠心病一级预防中的应用]
Wien Med Wochenschr. 1999;149(5-6):129-38.
3
[Meta-analysis of therapeutic trials of primary prevention in ischemic cardiopathies by hypocholesteremic treatment].[低胆固醇血症治疗对缺血性心脏病一级预防治疗试验的荟萃分析]
Arch Mal Coeur Vaiss. 1992 Sep;85 Spec No 2:105-8.
4
Prevention of coronary heart disease through cholesterol reduction.通过降低胆固醇预防冠心病。
Am Fam Physician. 1997 May 1;55(6):2250-8.
5
[Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease].[在冠心病二级预防中改善升高的血浆胆固醇水平]
Z Kardiol. 1995 Aug;84(8):577-95.
6
Total serum cholesterol and ischemic heart disease risk in clinical trials and observational studies.临床试验和观察性研究中的总血清胆固醇与缺血性心脏病风险
Am J Prev Med. 1985 Jul-Aug;1(4):18-24.
7
Will serum lipid lowering treatment reduce the incidence of coronary heart disease?血清降脂治疗会降低冠心病的发病率吗?
Artery. 1981;9(5):372-81.
8
Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).冠心病患者中提高高密度脂蛋白胆固醇的临床获益与血清低密度脂蛋白胆固醇水平的关系(来自苯扎贝特预防心肌梗死试验)
Am J Cardiol. 2009 Jan 1;103(1):41-5. doi: 10.1016/j.amjcard.2008.08.033. Epub 2008 Oct 10.
9
What do we gain by modifying risk factors for coronary disease?通过改变冠心病的危险因素,我们能获得什么?
Schweiz Med Wochenschr. 1990 Mar 17;120(11):359-64.
10
[Hypercholesterolemia: to treat or not to treat? That is the question].[高胆固醇血症:治疗还是不治疗?这是个问题]
Rev Med Brux. 1994 May-Jun;15(3):124-31.